keyword
MENU ▼
Read by QxMD icon Read
search

Dendritic cell immunotherapy

keyword
https://www.readbyqxmd.com/read/29675018/contribution-to-tumor-angiogenesis-from-innate-immune-cells-within-the-tumor-microenvironment-implications-for-immunotherapy
#1
REVIEW
Adriana Albini, Antonino Bruno, Douglas M Noonan, Lorenzo Mortara
The critical role of angiogenesis in promoting tumor growth and metastasis is strongly established. However, tumors show considerable variation in angiogenic characteristics and in their sensitivity to antiangiogenic therapy. Tumor angiogenesis involves not only cancer cells but also various tumor-associated leukocytes (TALs) and stromal cells. TALs produce chemokines, cytokines, proteases, structural proteins, and microvescicles. Vascular endothelial growth factor (VEGF) and inflammatory chemokines are not only major proangiogenic factors but are also immune modulators, which increase angiogenesis and lead to immune suppression...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29674449/induction-of-antitumor-cytotoxic-lymphocytes-using-engineered-human-primary-blood-dendritic-cells
#2
Long Wu, Huan Zhang, Yixing Jiang, Robert C Gallo, Hua Cheng
Dendritic cell (DC)-based cancer immunotherapy has achieved modest clinical benefits, but several technical hurdles in DC preparation, activation, and cancer/testis antigen (CTA) delivery limit its broad applications. Here, we report the development of immortalized and constitutively activated human primary blood dendritic cell lines (ihv-DCs). The ihv-DCs are a subset of CD11c+ /CD205+ DCs that constitutively display costimulatory molecules. The ihv-DCs can be genetically modified to express human telomerase reverse transcriptase (hTERT) or the testis antigen MAGEA3 in generating CTA-specific cytotoxic T lymphocytes (CTLs)...
April 19, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29673645/intranasal-delivery-of-adjuvant-free-peptide-nanofibers-elicits-resident-cd8-t-cell-responses
#3
Youhui Si, Yi Wen, Sean H Kelly, Anita S Chong, Joel H Collier
Influenza vaccines that can be administered intranasally or by other needle-free delivery routes have potential advantages over injected formulations in terms of patient compliance, cost, and ease of global distribution. Supramolecular peptide nanofibers have been investigated previously as platforms for vaccines and immunotherapies and have been shown to raise immune responses in the absence of exogenous adjuvants and without measurable inflammation. However, at present it has not been tested whether the immunogenicity of these materials extends to the intranasal route...
April 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29672857/bags-versus-flasks-a-comparison-of-cell-culture-systems-for-the-production-of-dendritic-cell-based-immunotherapies
#4
REVIEW
Natalie Fekete, Ariane V Béland, Katie Campbell, Sarah L Clark, Corinne A Hoesli
In recent years, cell-based therapies targeting the immune system have emerged as promising strategies for cancer treatment. This review summarizes manufacturing challenges related to production of antigen presenting cells as a patient-tailored cancer therapy. Understanding cell-material interactions is essential because in vitro cell culture manipulations to obtain mature antigen-producing cells can significantly alter their in vivo performance. Traditional antigen-producing cell culture protocols often rely on cell adhesion to surface-treated hydrophilic polystyrene flasks...
April 19, 2018: Transfusion
https://www.readbyqxmd.com/read/29670088/a-cancer-vaccine-mediated-postoperative-immunotherapy-for-recurrent-and-metastatic-tumors
#5
Tingting Wang, Dangge Wang, Haijun Yu, Bing Feng, Fangyuan Zhou, Hanwu Zhang, Lei Zhou, Shi Jiao, Yaping Li
Vaccines to induce effective and sustained antitumor immunity have great potential for postoperative cancer therapy. However, a robust cancer vaccine simultaneously eliciting tumor-specific immunity and abolishing immune resistance continues to be a challenge. Here we present a personalized cancer vaccine (PVAX) for postsurgical immunotherapy. PVAX is developed by encapsulating JQ1 (a BRD4 inhibitor) and indocyanine green (ICG) co-loaded tumor cells with a hydrogel matrix. Activation of PVAX by 808 nm NIR laser irradiation significantly inhibits the tumor relapse by promoting the maturation of dendritic cells and eliciting tumor infiltration of cytotoxic T lymphocytes...
April 18, 2018: Nature Communications
https://www.readbyqxmd.com/read/29669721/ppar-%C3%AE-contributes-to-immunity-by-cancer-vaccines-that-secrete-gm-csf
#6
Girija Goyal, Karrie Wong, Christopher J Nirschl, Nicholas Souders, Donna Neuberg, Niroshana Anandasabapathy, Glenn Dranoff
Peroxisome proliferator activated receptor-γ (PPARγ) is a lipid-activated nuclear receptor that promotes immune tolerance through effects on macrophages, dendritic cells (DCs), and regulatory T cells (Tregs). Granulocyte-macrophage colony stimulating factor (GM-CSF) induces PPARγ expression in multiple myeloid cell types. GM-CSF contributes to both immune tolerance and protection, but the role of PPARγ in these pathways is poorly understood. Here we reveal an unexpected stimulatory role for PPARγ in the generation of antitumor immunity with irradiated, GM-CSF-secreting tumor-cell vaccines (GVAX)...
April 18, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29669251/self-renewal-and-toll-like-receptor-signaling-sustain-exhausted-plasmacytoid-dendritic-cells-during-chronic-viral-infection
#7
Monica Macal, Yeara Jo, Simone Dallari, Aaron Y Chang, Jihong Dai, Shobha Swaminathan, Ellen J Wehrens, Patricia Fitzgerald-Bocarsly, Elina I Zúñiga
Although characterization of T cell exhaustion has unlocked powerful immunotherapies, the mechanisms sustaining adaptations of short-lived innate cells to chronic inflammatory settings remain unknown. During murine chronic viral infection, we found that concerted events in bone marrow and spleen mediated by type I interferon (IFN-I) and Toll-like receptor 7 (TLR7) maintained a pool of functionally exhausted plasmacytoid dendritic cells (pDCs). In the bone marrow, IFN-I compromised the number and the developmental capacity of pDC progenitors, which generated dysfunctional pDCs...
April 17, 2018: Immunity
https://www.readbyqxmd.com/read/29655599/plasma-from-some-cancer-patients-inhibits-adenoviral-ad5f35-vector-transduction-of-dendritic-cells
#8
Ping Jin, Wenjing Chen, Jiaqiang Ren, Steven Chen, Lauren Wood, Yingdong Zhao, Alan Remaley, Chauha Pham, Sheena Lian, Shutong Liu, Hui Liu, Steven Highfill, Jay A Berzofsky, David F Stroncek
BACKGROUND: Pooled AB serum is often used as a media supplement for cell culture but it has the potential to transmit infectious diseases. To avoid this risk, we used autologous plasma as a media supplement for manufacturing dendritic cells (DCs) for cancer immunotherapy. We noticed inconsistencies in the DCs and investigated their nature and cause. METHODS: Adenovirus human epidural growth factor receptor 2 (adHER2/neu) DCs for 21 patients were manufactured from autologous peripheral blood monocytes that were treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 for 3 days, transduced with Ad5f35HER2ECTM and then treated with lipopolysaccharide and interferon (IFN)-γ for 1 day...
April 11, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29651443/immature-dendritic-cell-therapy-confers-durable-immune-modulation-in-an-antigen-dependent-and-antigen-independent-manner-in-nonobese-diabetic-mice
#9
Jeannette Lo, Chang-Qing Xia, Ruihua Peng, Michael J Clare-Salzler
Dendritic cell (DC) immunotherapy has been effective for prevention of type 1 diabetes (T1D) in NOD mice but fails to protect if initiated after active autoimmunity. As autoreactivity expands inter- and intramolecularly during disease progression, we investigated whether DCs unpulsed or pulsed with β cell antigenic dominant determinants (DD), subdominant determinants (SD), and ignored determinants (ID) could prevent T1D in mice with advanced insulitis. We found that diabetes was significantly delayed by DC therapy...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29649510/ilt4-functions-as-a-potential-checkpoint-molecule-for-tumor-immunotherapy
#10
REVIEW
Aiqin Gao, Yuping Sun, Guangyong Peng
Immune checkpoint blockade therapy targeting CTLA4 and PD-1/PD-L1 is a promising strategy in the treatment of different types of cancers. However, the clinical success rates of these therapies are still moderate and varied among cancer types. Therefore, identification of alternative and novel checkpoint molecules or interrupting tolerogenic pathways is urgently needed for successful tumor immunotherapy. Immunoglobulin-like transcript 4 (ILT4) is as an immunosuppressive molecule predominantly expressed in myeloid cells, including monocytes, macrophages, dendritic cells and granulocytes...
April 9, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29643231/personalized-cancer-vaccine-effectively-mobilizes-antitumor-t-cell-immunity-in-ovarian-cancer
#11
Janos L Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphael Genolet, Petra Baumgartner, Brian J Stevenson, Christian Iseli, Denarda Dangaj, Brian Czerniecki, Aikaterini Semilietof, Julien Racle, Alexandra Michel, Ioannis Xenarios, Cheryl Chiang, Dimitri S Monos, Drew A Torigian, Harvey L Nisenbaum, Olivier Michielin, Carl H June, Bruce L Levine, Daniel J Powel, David Gfeller, Rosemarie Mick, Urania Dafni, Vincent Zoete, Alexandre Harari, George Coukos, Lana E Kandalaft
We conducted a pilot clinical trial testing a personalized vaccine generated by autologous dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC), which was injected intranodally in platinum-treated, immunotherapy-naïve, recurrent ovarian cancer patients. OCDC was administered alone (cohort 1, n = 5), in combination with bevacizumab (cohort 2, n = 10), or bevacizumab plus low-dose intravenous cyclophosphamide (cohort 3, n = 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events...
April 11, 2018: Science Translational Medicine
https://www.readbyqxmd.com/read/29627706/dendritic-cell-based-immunotherapy-for-solid-tumors
#12
REVIEW
Nam-Chul Jung, Jun-Ho Lee, Kwang-Hoe Chung, Yi Sub Kwak, Dae-Seog Lim
As a treatment for solid tumors, dendritic cell (DC)-based immunotherapy has not been as effective as expected. Here, we review the reasons underlying the limitations of DC-based immunotherapy for solid tumors and ask what can be done to improve immune cell-based cancer therapies. Several reports show that, rather than a lack of immune induction, the limited efficacy of DC-based immunotherapy in cases of renal cell carcinoma (RCC) likely results from inhibition of immune responses by tumor-secreted TGF-β and an increase in the number of regulatory T (Treg) cells in and around the solid tumor...
April 5, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29619065/-lycium-barbarum-polysaccharide-promotes-maturation-of-dendritic-cell-via-notch-signaling-and-strengthens-dendritic-cell-mediated-t-lymphocyte-cytotoxicity-on-colon-cancer-cell-ct26-wt
#13
Wei Wang, Mingxing Liu, Yang Wang, Tao Yang, Dongsheng Li, Feng Ding, Hongzhi Sun, Guang Bai, Qing Li
Lycium barbarum polysaccharide (LBP) is the major function component of Lycium barbarum L. and has been previously reported to induce the phenotypic and functional maturation of dendritic cells (DCs) as well as activating T lymphocytes. In the current study, the immunologic cytotoxicity promoting effect of LBP was assessed and the underlying mechanism was explored. The impact of LBP on the phenotype, maturation, and immunogenicity of DCs was assessed. The activity of Notch pathway which is involved in the regulation of LBP on DCs was detected...
2018: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29611470/polymeric-immunonanoparticles-mediated-cancer-therapy-versatile-nanocarriers-for-cell-specific-cargo-delivery
#14
Namdev L Dhas, Ritu R Kudarha, Niyati S Acharya, Sanjeev R Acharya
The major drawback with conventional therapeutic approaches for cancer therapy is decreased efficacy and redundant therapy associated toxicity and side effects causing increased patient discomfort. With the aim of minimizing these limitations, a vast amount of attention has been given to targeted nanocarrier-based drug delivery systems that possess a several-fold advantage over conventional therapy. Increased research in targeted nanoparticulate systems has led to the development of immunonanoparticles with enhanced efficacy and targeting efficiency along with decreased drug-resistant cancer- and dose-related toxicity...
2018: Critical Reviews in Therapeutic Drug Carrier Systems
https://www.readbyqxmd.com/read/29607690/antitumor-and-immunomodulatory-activities-of-ganoderma-lucidum-polysaccharides-in-glioma-bearing-rats
#15
Chunhua Wang, Songsheng Shi, Quan Chen, Shuqian Lin, Rui Wang, Saizhen Wang, Chunmei Chen
Malignant gliomas are the most common brain tumors with high rates of recurrence and mortality. Novel approaches are in research, and immunotherapy emerges as a promising strategy. Recently, scientific attention has been focused on Ganoderma lucidum polysaccharides (GL-PS), one of the critical bioactive components of G lucidum, which have been recognized as a promising natural source of immunomodulatory and anticancer compounds. It remains unknown whether the GL-PS have any immunomodulatory and anticancer effects on brain glioma...
March 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29601471/nanopulse-stimulation-nps-induces-tumor-ablation-and-immunity-in-orthotopic-4t1-mouse-breast-cancer-a-review
#16
REVIEW
Stephen J Beebe, Brittany P Lassiter, Siqi Guo
Nanopulse Stimulation (NPS) eliminates mouse and rat tumor types in several different animal models. NPS induces protective, vaccine-like effects after ablation of orthotopic rat N1-S1 hepatocellular carcinoma. Here we review some general concepts of NPS in the context of studies with mouse metastatic 4T1 mammary cancer showing that the postablation, vaccine-like effect is initiated by dynamic, multilayered immune mechanisms. NPS eliminates primary 4T1 tumors by inducing immunogenic, caspase-independent programmed cell death (PCD)...
March 30, 2018: Cancers
https://www.readbyqxmd.com/read/29600445/tumor-lysate-based-vaccines-on-the-road-to-immunotherapy-for-gallbladder-cancer
#17
REVIEW
Daniel Rojas-Sepúlveda, Andrés Tittarelli, María Alejandra Gleisner, Ignacio Ávalos, Cristián Pereda, Iván Gallegos, Fermín Eduardo González, Mercedes Natalia López, Jean Michel Butte, Juan Carlos Roa, Paula Fluxá, Flavio Salazar-Onfray
Immunotherapy based on checkpoint blockers has proven survival benefits in patients with melanoma and other malignancies. Nevertheless, a significant proportion of treated patients remains refractory, suggesting that in combination with active immunizations, such as cancer vaccines, they could be helpful to improve response rates. During the last decade, we have used dendritic cell (DC) based vaccines where DCs loaded with an allogeneic heat-conditioned melanoma cell lysate were tested in a series of clinical trials...
March 29, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29599770/dendritic-cells-and-programmed-death-1-blockade-a-joint-venture-to-combat-cancer
#18
REVIEW
Maarten Versteven, Johan M J Van den Bergh, Elly Marcq, Evelien L J Smits, Viggo F I Van Tendeloo, Willemijn Hobo, Eva Lion
Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have proved that this type of personalized medicine is safe and has the capacity to improve survival, but monotherapy is unlikely to cure the cancer. Designed to empower the patient's antitumor immunity, huge research efforts are set to improve the efficacy of next-generation DC vaccines and to find synergistic combinations with existing cancer therapies. Immune checkpoint approaches, aiming to breach immune suppression and evasion to reinforce antitumor immunity, have been a revelation in the immunotherapy field...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29588348/intratumoral-cpg-b-promotes-anti-tumoral-neutrophil-cdc-and-t-cell-cooperation-without-reprograming-tolerogenic-pdc
#19
Marion Humbert, Leslie Guery, Dale Brighouse, Sylvain Lemeille, Stephanie Hugues
Cancer immunotherapies utilize distinct mechanisms to harness the power of the immune system to eradicate cancer cells. Therapeutic vaccines, aimed at inducing active immune responses against an existing cancer, are highly dependent on the immunological microenvironment, where many immune cell types display high levels of plasticity and, depending on the context, promote very different immunological outcomes. Among them, plasmacytoid dendritic cells (pDC), known to be highly immunogenic upon inflammation, are maintained in a tolerogenic state by the tumor microenvironment...
March 27, 2018: Cancer Research
https://www.readbyqxmd.com/read/29575270/the-immunomodulatory-role-of-tumour-derived-extracellular-vesicles-in-colorectal-cancer
#20
Stephanie Manning, Kirsty M Danielson
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide with rising mortality rates predicted in the coming decades. In light of this, there is a continued need for improvement in our understanding of CRC biology and the development of novel treatment options. Tumour-derived extracellular vesicles (tEVs) have emerged as both novel cancer biomarkers and functional mediators of carcinogenesis. tEVs are released by tumour cells in abundance and play an important role in mediating tumour cell - immune cell interactions in the tumour microenvironment...
March 25, 2018: Immunology and Cell Biology
keyword
keyword
71627
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"